Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sozinibercept (OPT-302) + Aflibercept in wet AMD (COAST)
NCT04757636Phase 3Terminated
- Sponsor
- Opthea Limited
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of sozinibercept in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Opthea Limited. Primary endpoint: Mean Change in Early Treatment Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letters at 52 weeks. Started Mar 2021; status: terminated.
02
Drugs
sozinibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04757636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757636.